PAS (Post-Approval Study to Evaluate the Safety and Effectiveness of the Eversense Continuous Glucose Monitoring (CGM) System Used Non-adjunctively)
Research payments
$1,008,682
Through program year 2021, $1,008,682 in research payments was reported against PAS (Post-Approval Study to Evaluate the Safety and Effectiveness of the Eversense Continuous Glucose Monitoring (CGM) System Used Non-adjunctively), across 79 payments, paid by Senseonics, Incorporated.
- Paid by
- Senseonics, Incorporated
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $553,965 | 55 |
| 2020 | Research | $248,104 | 16 |
| 2019 | Research | $206,613 | 8 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Alan Schorr Langhorne, PA Named on 23 payments
- Sam Lerman Hollywood, FL Named on 20 payments
- Robert Busch Albany, NY Named on 9 payments
- Mark Warren Greenville, NC Named on 6 payments
- Joseph Soufer Waterbury, CT Named on 5 payments
- Hien Tran Round Rock, TX Named on 3 payments
- Ralph Oiknine Chesterfield, MO Named on 3 payments
- David Ahn Newport Beach, CA Named on 3 payments
- Kashif Latif Bartlett, TN Named on 2 payments
- Lori Gerard Englewood, CO Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.